NEWS : CIMS Healthcare Excellence Awards 2017- Best Hospital Unit in Oncology & Individual Excellence in the field of Operations * Padmashree Dr. Ramakant Deshpande, Executive Chairman and Director of ACI, receiving an award for the Best Healthcare Entrepreneur at Global Awards for Excellence in Quality Management & Leadership * ACI DAYCARE-BORIVALI 4 Feb launching of centre by the hands of cabinet Minister Shree Vinod Tawde & sitting MP Shree Gopal Shetty * Click Here To Take Appointment!!! * We have Sucessfully performed 250 Robotic Surgery till date *
BLOG : Afatinib Superior to Erlotinin Liquid Biopsy gives 100% accuracy Head and Neck New Urinary Molecular Test

This is summary of data presented on MONDAY, March 21, 2016 at the annual meeting of the Society of Gynecologic Oncology, USA.
Genetic testing form DNA from blood or tumors or both from 1,195 women using a gene panel test, BROCA-HR detected that 25.6 percent of the women had a mutation in at least one gene affecting DNA repair.

All of the women who carried mutations in DNA repair genes had significantly better progression-free and overall survival when compared to those with no mutations.

For example, for women with mutations in the BRCA1gene, the Average progression-free survival was 15.7 months, while their overall survival was 55.3 months.

For those with BRCA2mutations, median progression-free survival was 21.6 months, while overall survival was 75.2 months.

Left Menu Icon